Dolasetron mesylate monhydate CAS NO.115956-13-3
Active Pharmaceutical Ingredients 2025-03-03
Catalog ID80017551
CAS NO.115956-13-3
Purity 96%
MDL NumberMFCD01718979
olecular formula C19H20N2O3.CH4O3S.H2O
Molecular weight 438.4946
Melting point: 160~165°C
| Aspect | Details |
|---|---|
| Chemical Structure | Dolasetron mesylate monohydrate is a selective serotonin subtype 3 (5-HT3) receptor antagonist. Its empirical formula is C19H20N2O3·CH3SO3H·H2O, with a molecular weight of 438.50. |
| Chemical Properties | – White to off-white powder.<br>- Freely soluble in water and propylene glycol, slightly soluble in ethanol and normal saline. |
| Mechanism of Action | Acts as a selective 5-HT3 receptor antagonist, reducing nausea and vomiting by blocking serotonin released from enterochromaffin cells in the small intestine. |
| Indications | – Prevention and treatment of postoperative nausea and vomiting (PONV) in adults and children aged 2 years and older.<br>- Not recommended for routine prophylaxis in patients with low risk of PONV. |
| Administration | – Intravenous: Can be infused rapidly (within 30 seconds) or diluted and infused over up to 15 minutes.<br>- Oral: For pediatric patients, the injection solution can be mixed with apple or apple-grape juice. |
| Dosage | – Intravenous: 12.5 mg dose is effective for preventing PONV.<br>- Pediatric Oral: 1.2 mg/kg up to a maximum of 100 mg, given within 2 hours before surgery. |
| Storage Conditions | Store at 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F). Protect from light. |
| Contraindications | – Hypersensitivity to dolasetron.<br>- Intravenous use is contraindicated for preventing nausea and vomiting associated with cancer chemotherapy due to QT prolongation. |
| Special Considerations | – ECG monitoring recommended for elderly and renally impaired patients.<br>- Stability: Diluted solution is stable at room temperature for 24 hours or under refrigeration for 48 hours. |
| Adverse Effects | – Common: Headache, dizziness, somnolence.<br>- Rare: QT prolongation, arrhythmias |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
